Where Will Viking Therapeutics Be in 5 Years?

Five years ago, Viking Therapeutics (NASDAQ: VKTX) was an unknown, clinical-stage biotech. It hardly stood out in a sea of small drugmakers, and most of those never end up producing the kinds of results or performances investors want to see.However, a lot has changed since: Viking still has no products on the market, but its leading candidates have made exciting clinical progress. That's why its shares soared this year.There is still a lot of work ahead for this biotech, though. How will it evolve over the next half-decade? Let's try to figure it out.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool